Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib and Nivolumab in Myelofibrosis
NCT05393674Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of fedratinib, nivolumab in myelofibrosis (MF), sponsored by Institut für Klinische Krebsforschung. Started Jun 2022; status: completed.
02
Drugs
fedratinibnivolumab
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05393674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393674.